Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 7, 2000
Last updated: August 23, 2013
Last verified: November 2011

March 7, 2000
August 23, 2013
August 1999
Not Provided
  • Safety [ Designated as safety issue: Yes ]
  • Response [ Designated as safety issue: No ]
  • Markers of angiogenesis [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00004876 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of ovarian cancer by stopping blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying how well giving carboplatin together with thalidomide works compared to carboplatin alone in treating patients with ovarian epithelial cancer.


  • Determine the safety of carboplatin and thalidomide in patients with stage IC-IV ovarian cancer.
  • Determine the antiangiogenic effect of thalidomide in this patient population.
  • Compare the efficacy of carboplatin with or without thalidomide in this patient population.

OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive carboplatin IV over 1 hour. Treatment continues every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive carboplatin as in arm I. Patients receive thalidomide orally once daily. Thalidomide treatment continues for up to 24 weeks commencing on the first day of carboplatin therapy and ceasing 4 weeks after the last course of carboplatin.

PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.

Phase 2
Allocation: Randomized
Primary Purpose: Treatment
Ovarian Cancer
  • Drug: carboplatin
  • Drug: thalidomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided


  • Histologically confirmed stage IC-IV ovarian epithelial cancer
  • Post-menopausal OR
  • Prior bilateral salpingo-oophorectomy and/or total abdominal hysterectomy



  • Over 18

Performance status:

  • WHO 0-2

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No other concurrent invasive malignancies
  • Not pregnant
  • No diabetes mellitus
  • No chronic neurological disease causing peripheral neuropathy


Biologic therapy:

  • Not specified


  • No other concurrent cytotoxic agents

Endocrine therapy:

  • Not specified


  • Concurrent local radiotherapy for treatment of secondary disease sites allowed


  • See Disease Characteristics
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
CDR0000067536, ICRF-96.084, EU-99018
Not Provided
Not Provided
Not Provided
Not Provided
Cancer Research UK
Not Provided
Study Chair: T.S. Ganesan, MD Oxford University Hospitals NHS Trust
National Cancer Institute (NCI)
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP